COMPASS PATHWAYS PLC Deferred Costs, Current
COMPASS PATHWAYS PLC (CMPS) had Deferred Costs, Current of $0 as of 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current
us-gaap:DeferredCostsCurrent · last filed 2023-02-28
- 2022-12-31: Deferred Costs, Current $0.00.
- 2022-09-30: Deferred Costs, Current $0.00.
- 2022-06-30: Deferred Costs, Current $0.00.
- 2022-03-31: Deferred Costs, Current $817.00K.
| Period end | Deferred Costs, Current |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 |
| 2022-03-31 | $817.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | $840.00K 10-K · filed 2023-02-28 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |